LONDON & OXFORD, England--(BUSINESS WIRE)--Today, LGC announced the acquisition of The Native Antigen Company (NAC), one of the world’s leading suppliers of high quality infectious disease antigens and antibodies.
There is increasing regulatory pressure on pharmaceutical companies to investigate the potential interaction between a dosage form and the primary closure and transfer system employed. A thorough scientifically sound extractables and leachables (E&L) programme is, therefore, an essential regulatory requirement.